Publication:
Predictive value of homologous recombination deficiency status for survival outcomes in primary tubo-ovarian high-grade serous carcinoma

Simple item page
dc.contributor.coauthorZwimpfer T.A., Ewald H., Jayawardana M., Appenzeller-Herzog C., Bizzarri N., Razumova Z., Kacperczyk-Bartnik J., Heinzelmann-Schwarz V., Friedlander M., Bowtell D.D.L., Garsed D.W.
dc.contributor.departmentGraduate School of Health Sciences
dc.contributor.kuauthorBilir, Esra
dc.contributor.schoolcollegeinstituteGRADUATE SCHOOL OF HEALTH SCIENCES
dc.date.accessioned2025-03-06T20:57:49Z
dc.date.issued2024
dc.description.abstractObjectives: This is a protocol for a Cochrane Review (prognosis). The objectives are as follows:. To evaluate the predictive value of the prognostic factor HRD status, as determined by various clinically validated HRD assays at the time of staging laparotomy, compared to BRCA1/2 mutation status for progression-free survival and overall survival in patients with tubo-ovarian high-grade serous carcinoma treated in the first-line setting with a combination of surgery and platinum-based chemotherapy and/or maintenance with PARP inhibitors. Copyright © 2024 The Cochrane Collaboration. Published by John Wiley and Sons, Ltd.
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipThe following people conducted the editorial process for this article: Sign-off Editor (final editorial decision): Jo Morrison, Department of Gynaecological Oncology, Taunton, Somerset Managing Editor (selected peer reviewers, provided editorial guidance to authors, edited the article): Liz Bickerdike, Cochrane Central Editorial Service Editorial Assistant (conducted editorial policy checks, collated peer reviewer comments, and supported the editorial team): Leticia Rodrigues, Cochrane Central Editorial Service Copy Editor (copy editing and production): Jenny Bellorini, Cochrane Central Production Service Peer reviewers (provided comments and recommended an editorial decision): Rachel Richardson, Cochrane (methods);Anneke Damen, Cochrane Netherlands, University Medical Center Utrecht (methods);Maria-Inti Metzendorf, Institute of General Practice, Medical Faculty of the Heinrich Heine University, D\u00FCsseldorf, Germany (search);Amir A. Jazaeri, MD Professor and Vice Chair for Clinical Research Department of Gynecologic Oncology and Reproductive Medicine University of Texas, MD Anderson Cancer Center (clinical);Karen Cadoo, St James's Hospital Dublin, Trinity College, Dublin, Trinity St. James's Cancer Center (clinical) Sign-off Editor (final editorial decision): Jo Morrison, Department of Gynaecological Oncology, Taunton, Somerset Managing Editor (selected peer reviewers, provided editorial guidance to authors, edited the article): Liz Bickerdike, Cochrane Central Editorial Service Editorial Assistant (conducted editorial policy checks, collated peer reviewer comments, and supported the editorial team): Leticia Rodrigues, Cochrane Central Editorial Service Copy Editor (copy editing and production): Jenny Bellorini, Cochrane Central Production Service Peer reviewers (provided comments and recommended an editorial decision): Rachel Richardson, Cochrane (methods);Anneke Damen, Cochrane Netherlands, University Medical Center Utrecht (methods);Maria-Inti Metzendorf, Institute of General Practice, Medical Faculty of the Heinrich Heine University, D\u00FCsseldorf, Germany (search);Amir A. Jazaeri, MD Professor and Vice Chair for Clinical Research Department of Gynecologic Oncology and Reproductive Medicine University of Texas, MD Anderson Cancer Center (clinical);Karen Cadoo, St James's Hospital Dublin, Trinity College, Dublin, Trinity St. James's Cancer Center (clinical)
dc.identifier.doi10.1002/14651858.CD015896
dc.identifier.grantnoTrinity College, University of Oxford
dc.identifier.issn1465-1858
dc.identifier.issue9
dc.identifier.quartileN/A
dc.identifier.scopus2-s2.0-85204760219
dc.identifier.urihttps://doi.org/10.1002/14651858.CD015896
dc.identifier.urihttps://hdl.handle.net/20.500.14288/27323
dc.identifier.volume2024
dc.keywordsCystadenocarcinoma, serous
dc.keywordsFallopian tube neoplasms
dc.keywordsGenes, BRCA1
dc.keywordsGenes, BRCA2
dc.keywordsMutation
dc.keywordsOvarian neoplasms
dc.keywordsPrognosis
dc.keywordsProgression-free survival
dc.language.isoeng
dc.publisherJohn Wiley and Sons Ltd
dc.relation.ispartofCochrane Database of Systematic Reviews
dc.subjectMedicine
dc.titlePredictive value of homologous recombination deficiency status for survival outcomes in primary tubo-ovarian high-grade serous carcinoma
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorBilir, Esra
local.publication.orgunit1GRADUATE SCHOOL OF HEALTH SCIENCES
local.publication.orgunit2Graduate School of Health Sciences
relation.isOrgUnitOfPublication2f870f28-12c9-4b28-9465-b91a69c1d48c
relation.isOrgUnitOfPublication.latestForDiscovery2f870f28-12c9-4b28-9465-b91a69c1d48c
relation.isParentOrgUnitOfPublication4c75e0a5-ca7f-4443-bd78-1b473d4f6743
relation.isParentOrgUnitOfPublication.latestForDiscovery4c75e0a5-ca7f-4443-bd78-1b473d4f6743

Files

Collections

Publications without Fulltext